CoChat

Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease

Open access

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is a slowly progressive hereditary disorder that usually leads to end-stage renal disease. Although the underlying gene mutations were identified several years ago, efficacious therapy to curtail cyst growth and prevent renal failure is not available. Experimental and observational studies suggest that the mammalian target of rapamycin (mTOR) pathway plays a critical role in cyst growth. METHODS: In this 2-year, double-blind trial, we randomly assigned 433 patients with ADPKD to receive either placebo or the mTOR inhibitor everolimus. The primary outcome was the change in total kidney volume, as measured on magnetic resonance imaging, at 12 and 24 months. RESULTS: Total kidney volume increased between baseline and 1 year by 102 ml in the everolimus group, versus 157 ml in the placebo group (P=0.02) and between baseline and 2 years by 230 ml and 301 ml, respectively (P=0.06). Cyst volume increased by 76 ml in the everolimus group and 98 ml in the placebo group after 1 year (P=0.27) and by 181 ml and 215 ml, respectively, after 2 years (P=0.28). Parenchymal volume increased by 26 ml in the everolimus group and 62 ml in the placebo group after 1 year (P=0.003) and by 56 ml and 93 ml, respectively, after 2 years (P=0.11). The mean decrement in the estimated glomerular filtration rate after 24 months was 8.9 ml per minute per 1.73 m2 of body-surface area in the everolimus group versus 7.7 ml per minute in the placebo group (P=0.15). Drug-specific adverse events were more common in the everolimus group; the rate of infection was similar in the two groups. CONCLUSIONS: Within the 2-year study period,as compared with placebo, everolimus slowed the increase in total kidney volume of patients with ADPKD but did not slow the progression of renal impairment [corrected]. (Funded by Novartis; EudraCT number, 2006-001485-16; ClinicalTrials.gov number, NCT00414440.)

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmoa1003491

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 21 references

Cited by

Metadata

Authors
Walz, G., Budde, K., Mannaa, M., Nürnberger, J., Wanner, C., Sommerer, C., Kunzendorf, U., Banas, B., Hörl, W. H., Obermüller, N., Arns, W., Pavenstädt, H., Gaedeke, J., Büchert, M., May, C., Gschaidmeier, H., Kramer, S., & Eckardt, K.-U.
Affiliations
  • University Medical Center Freiburg (DE)
  • Charité – Universitätsmedizin Berlin (DE)
  • University of Duisburg-Essen (DE)
  • Universitätsklinikum Würzburg (DE)
  • University Hospital Heidelberg (DE)
  • University Hospital Schleswig-Holstein (DE)
  • University Hospital Regensburg (DE)
  • Medical University of Vienna (AT)
  • University Hospital Frankfurt (DE)
  • Lungenklinik Köln-Merheim (DE)
  • University Hospital Münster (DE)
  • Novartis (Germany) (DE)
  • Universitätsklinikum Erlangen (DE)
Venue
New England Journal of Medicine
Published
2010-08-26
Volume
363
Issue
9
Pages
830-840
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2082060108
Cited by
587
References
21
Citations by year
2026: 15 · 2025: 18 · 2024: 14 · 2023: 26 · 2022: 32 · 2021: 20 · 2020: 34 · 2019: 37 · 2018: 40 · 2017: 40 · 2016: 47 · 2015: 54 · 2014: 53 · 2013: 49 · 2012: 44
FWCI
28.03
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • University of Regensburg Publication Server (University of Regensburg) (acceptedVersion)
  • Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
  • Health Sciences › Medicine › Genetics (clinical) › Tuberous Sclerosis Complex Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
Keywords
autosomal dominant polycystic kidney disease, everolimus, mTOR inhibitors, kidney cyst growth, total kidney volume, glomerular filtration rate decline, renal fibrosis, end-stage renal disease prevention, infection risk
MeSH terms
Everolimus, Adult, Cholesterol, Creatinine, Double-Blind Method, Female, Glomerular Filtration Rate, Humans, Kidney, Kidney Failure, Chronic, Male, Organ Size, Polycystic Kidney, Autosomal Dominant, Protein Serine-Threonine Kinases, Disease Progression, Sirolimus, Intracellular Signaling Peptides and Proteins, Young Adult, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.